Key Considerations When Outsourcing Cell-Culture Medium Development - The authors examine several issues that will help streamline negotiations between a service provider and a cell-culture medium con

ADVERTISEMENT

Key Considerations When Outsourcing Cell-Culture Medium Development
The authors examine several issues that will help streamline negotiations between a service provider and a cell-culture medium consumer.


BioPharm International Supplements
Volume 24, Issue 3, pp. s15-s18

Conclusion

Although not a comprehensive listing, the areas discussed in this article are four of the most important issues that will help to streamline the negotiations between a service provider and a project sponsor interested in partnering on the development of a cell-culture medium. As the technology platforms continue to push new boundaries, we will need to continue to look for new ways to realize and share the value of those discoveries. The collective lesson for our industry has been that technical innovations in products and services must be matched with business innovation to continue to best serve patients.

It is clear that striking a balanced approach to the outsourcing discussion is crucial for achieving the project goals. An imbalance in any of the four areas discussed will set the outsourcing relationship on the course to disappointment; however, if done properly, a progressive philosophy on sharing risks and benefits will turn an arm's-length outsourcing relationship into a productive collaboration.

Acknowledgments

The authors wish to thank Cindy Goldstein and Laurie Donahue-Hjelle for their editorial contributions to this article.

TRENT CARRIER is General Manager of PD-Direct Services, STEVE GORFIEN is an R&D Director—Cell Culture Products and Services, and BRIAN GRIFFITH is Division Contracts Counsel, all at Life Technologies,
.

References

1. H. Eagle, Science, 122 (3168), 501–504 (1955).

2. Therapeutic Monoclonal Antibodies: World Market 2010–2015, http://ReportLinker.com/ 2010.

3. W.C. Paul et al., BioProcess Int. 7 (8), (2009).

4. D. Zhao et al., Biopharm Int. 21 (6) (2008).

5. T. Carrier et al., "High Throughput Technologies in Bioprocess Development," in Encyc. of Indust. Biotech., M. Flickinger, Ed. (Wiley, Hoboken, NJ, 2009).

6. S. Morris, BioProcess Int. 21 (12), 22-26, (2008).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here